PT-141
Bremelanotide
A melanocortin receptor agonist and synthetic analog of alpha-MSH. FDA-approved for premenopausal women with hypoactive sexual desire disorder (HSDD).
Typical Cost
$600-1000/month
Status
Research
Peptide Profile
PT-141
Mechanism of Action
Activates melanocortin receptors (MC1R, MC3R, MC4R) in the central nervous system, increasing sexual arousal and desire through central mechanisms rather than peripheral blood flow.
Common Dosages
subcutaneous
1.75mg
As needed (45 min before activity) · Max 8 doses/month
Benefits
Increased sexual desire
Enhanced arousal
Works in women with HSDD
On-demand dosing
Non-hormonal mechanism
Side Effects
Nausea (40%)
Vomiting
Flushing
Injection site reactions
Headache
Blood pressure elevation
Key Research
Bremelanotide phase III trials
FDA approval based on significant improvement in sexual desire and reduced distress in premenopausal women
Regulatory Status
FDA-approved (Vyleesi) for premenopausal women with HSDD. Not approved for men or postmenopausal women. Prescription required.
Contraindications
- ⚠Uncontrolled hypertension
- ⚠Cardiovascular disease
- ⚠Hepatic impairment
- ⚠Pregnancy
GLP-1 users experiencing libido changes during weight loss may benefit from sexual health support. SeraVia Vitality+ Multi supports overall hormonal balance.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.